20,089 reports of this reaction
18.2% of all NIRMATRELVIR AND RITONAVIR reports
#2 most reported adverse reaction
DISEASE RECURRENCE is the #2 most commonly reported adverse reaction for NIRMATRELVIR AND RITONAVIR, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 20,089 FDA adverse event reports linking NIRMATRELVIR AND RITONAVIR to DISEASE RECURRENCE. This represents approximately 18.2% of all 110,406 adverse event reports for this drug.
NIRMATRELVIR AND RITONAVIR has an overall safety score of 75 out of 100. Patients taking NIRMATRELVIR AND RITONAVIR who experience disease recurrence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE RECURRENCE is a frequently reported adverse event for NIRMATRELVIR AND RITONAVIR, accounting for a significant proportion of all reports.
In addition to disease recurrence, the following adverse reactions have been reported for NIRMATRELVIR AND RITONAVIR:
The following drugs have also been linked to disease recurrence in FDA adverse event reports:
DISEASE RECURRENCE has been reported as an adverse event in 20,089 FDA reports for NIRMATRELVIR AND RITONAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE RECURRENCE accounts for approximately 18.2% of all adverse event reports for NIRMATRELVIR AND RITONAVIR, making it one of the most commonly reported side effect.
If you experience disease recurrence while taking NIRMATRELVIR AND RITONAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.